These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 38432933)
1. [Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes]. Kurokawa J; Shimizu S; Sakamoto K Yakugaku Zasshi; 2024; 144(3):251-255. PubMed ID: 38432933 [TBL] [Abstract][Full Text] [Related]
2. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives]. Yanagida S; Kawagishi H; Kanda Y Nihon Yakurigaku Zasshi; 2024; 159(2):83-89. PubMed ID: 38432924 [TBL] [Abstract][Full Text] [Related]
3. [Prediction of Cardiac Toxicity by Anti-cancer Drugs Using iPSC Cardiomyocytes]. Yanagida S; Kanda Y Yakugaku Zasshi; 2024; 144(3):265-271. PubMed ID: 38432935 [TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology. Satsuka A; Kanda Y Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543 [TBL] [Abstract][Full Text] [Related]
5. Chronic drug-induced effects on contractile motion properties and cardiac biomarkers in human induced pluripotent stem cell-derived cardiomyocytes. Kopljar I; De Bondt A; Vinken P; Teisman A; Damiano B; Goeminne N; Van den Wyngaert I; Gallacher DJ; Lu HR Br J Pharmacol; 2017 Nov; 174(21):3766-3779. PubMed ID: 28094846 [TBL] [Abstract][Full Text] [Related]
6. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity. Yang X; Papoian T J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688 [TBL] [Abstract][Full Text] [Related]
7. Development of In Vitro Drug-Induced Cardiotoxicity Assay by Using Three-Dimensional Cardiac Tissues Derived from Human Induced Pluripotent Stem Cells. Takeda M; Miyagawa S; Fukushima S; Saito A; Ito E; Harada A; Matsuura R; Iseoka H; Sougawa N; Mochizuki-Oda N; Matsusaki M; Akashi M; Sawa Y Tissue Eng Part C Methods; 2018 Jan; 24(1):56-67. PubMed ID: 28967302 [TBL] [Abstract][Full Text] [Related]
8. Chronic Cardiotoxicity Assays Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs). Narkar A; Willard JM; Blinova K Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328619 [TBL] [Abstract][Full Text] [Related]
9. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Feaster TK; Cadar AG; Wang L; Williams CH; Chun YW; Hempel JE; Bloodworth N; Merryman WD; Lim CC; Wu JC; Knollmann BC; Hong CC Circ Res; 2015 Dec; 117(12):995-1000. PubMed ID: 26429802 [TBL] [Abstract][Full Text] [Related]
10. Speckle-Tracking Strain Analysis for Mapping Spatiotemporal Contractility of Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocytes. Izadifar M; Berecz T; Li B; Tang JKKY; Foldes G; Apati A; Nagy A Curr Protoc; 2023 Sep; 3(9):e889. PubMed ID: 37747346 [TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes. Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214 [TBL] [Abstract][Full Text] [Related]
12. Cardiotoxicity and Heart Failure: Lessons from Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Anticancer Drugs. Sachinidis A Cells; 2020 Apr; 9(4):. PubMed ID: 32316481 [TBL] [Abstract][Full Text] [Related]
13. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760 [TBL] [Abstract][Full Text] [Related]
14. Measuring the contractile forces of human induced pluripotent stem cell-derived cardiomyocytes with arrays of microposts. Rodriguez ML; Graham BT; Pabon LM; Han SJ; Murry CE; Sniadecki NJ J Biomech Eng; 2014 May; 136(5):051005. PubMed ID: 24615475 [TBL] [Abstract][Full Text] [Related]
15. An In Silico Platform to Predict Cardiotoxicity Risk of Anti-tumor Drug Combination with hiPSC-CMs Based In Vitro Study. Sang L; Zhou Z; Luo S; Zhang Y; Qian H; Zhou Y; He H; Hao K Pharm Res; 2024 Feb; 41(2):247-262. PubMed ID: 38148384 [TBL] [Abstract][Full Text] [Related]
16. Integrating nonlinear analysis and machine learning for human induced pluripotent stem cell-based drug cardiotoxicity testing. Kowalczewski A; Sakolish C; Hoang P; Liu X; Jacquir S; Rusyn I; Ma Z J Tissue Eng Regen Med; 2022 Aug; 16(8):732-743. PubMed ID: 35621199 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes. Lee S; Lee HA; Choi SW; Kim SJ; Kim KS Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276 [TBL] [Abstract][Full Text] [Related]
19. Recent advances in pluripotent stem cell-derived cardiac organoids and heart-on-chip applications for studying anti-cancer drug-induced cardiotoxicity. Liu S; Fang C; Zhong C; Li J; Xiao Q Cell Biol Toxicol; 2023 Dec; 39(6):2527-2549. PubMed ID: 37889357 [TBL] [Abstract][Full Text] [Related]
20. Human Induced Pluripotent Stem-Cardiac-Endothelial-Tumor-on-a-Chip to Assess Anticancer Efficacy and Cardiotoxicity. Weng KC; Kurokawa YK; Hajek BS; Paladin JA; Shirure VS; George SC Tissue Eng Part C Methods; 2020 Jan; 26(1):44-55. PubMed ID: 31797733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]